On the DRP interim conference call
, the question about efficacy in the various DRP subtypes was broached by Leerink analyst Marc Goodman (his question begins at 34:36). Serge said he wasn't in a position to provide details, but did note that "all dementia subtypes were represented across both the enrolled population and randomized population as well as across the adjudicated relapses," so a consistency was seen across all the DRP subtypes. Serge's answer begins at 35:28 of the call.
To reiterate, those with Alzheimer's psychosis, Lewy body dementia, Parkinson's dementia, vascular dementia, and frontotemporal dementia showed a strong enough response in the 12-week open-label portion of the study to continue to randomization. 20% of this total population did not show a strong enough response and were dismissed, while a tiny percentage discontinued the study for various reasons. A little under 80% of the enrolled population continued to randomization.
According to Serge, a number of patients on drug completed the full 38-week trial (that is, they did not experience a relapse). He also said the "number of patients randomized exceeded our initial expectations."
Further data analysis will probably be given on the 3Q call in November. Some analysts think a full DRP presentation will be given at CTAD